Cargando…
The potential of lasmiditan in migraine
Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT(1F)) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on posit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739205/ https://www.ncbi.nlm.nih.gov/pubmed/33403005 http://dx.doi.org/10.1177/1756286420967847 |